GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » FCF Margin %

Tesaro (Tesaro) FCF Margin % : -202.16% (As of Sep. 2018)


View and export this data going back to 2012. Start your Free Trial

What is Tesaro FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tesaro's Free Cash Flow for the three months ended in Sep. 2018 was $-130.2 Mil. Tesaro's Revenue for the three months ended in Sep. 2018 was $64.4 Mil. Therefore, Tesaro's FCF Margin % for the quarter that ended in Sep. 2018 was -202.16%.

As of today, Tesaro's current FCF Yield % is -13.27%.

The historical rank and industry rank for Tesaro's FCF Margin % or its related term are showing as below:

TSRO' s FCF Margin % Range Over the Past 10 Years
Min: -261.29   Med: 0   Max: 0
Current: -261.29


TSRO's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.935 vs TSRO: -261.29


Tesaro FCF Margin % Historical Data

The historical data trend for Tesaro's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro FCF Margin % Chart

Tesaro Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
FCF Margin %
Get a 7-Day Free Trial - - -67,456.15 -690.51 -208.56

Tesaro Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.98 -365.77 -300.05 -206.45 -202.16

Competitive Comparison of Tesaro's FCF Margin %

For the Biotechnology subindustry, Tesaro's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tesaro's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tesaro's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tesaro's FCF Margin % falls into.



Tesaro FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tesaro's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=-465.764/223.326
=-208.56 %

Tesaro's FCF Margin for the quarter that ended in Sep. 2018 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2018 )/Revenue (Q: Sep. 2018 )
=-130.192/64.399
=-202.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tesaro FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tesaro's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tesaro (Tesaro) Business Description

Traded in Other Exchanges
N/A
Address
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.
Executives
Mary Lynne Hedley director, officer: President & COO C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr. officer: SVP & Chief Medical Officer C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr director, officer: Chief Executive Officer C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson officer: Exec. VP, CFO C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle officer: Sr. VP, Chief Commercial Ofc C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg director
Joseph L Farmer officer: Sr VP, Gen Counsel & Secretary C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins 10 percent owner

Tesaro (Tesaro) Headlines

From GuruFocus